1 -4 Although a considerable amount of scientific evidence suggests a role for free radicals in the pathology of ischemia, the actual presence of free radicals during ischemia and reperfusion in the brain, unlike in the heart and other organs, has been difficult to demonstrate.
LY178002 Reduces Rat Brain Damage After Transient Global Forebrain Ischemia
O xidative damage caused by free radical production and lipid peroxidation as well as by products of the arachidonic acid cascade have been postulated to be primary factors in the acute-stage pathology of ischemic brain.
1 -4 Although a considerable amount of scientific evidence suggests a role for free radicals in the pathology of ischemia, the actual presence of free radicals during ischemia and reperfusion in the brain, unlike in the heart and other organs, has been difficult to demonstrate.
Increases in the amounts of free fatty acids 5 after ischemia and during early reperfusion can provide the substrate for lipid peroxidation and for the formation of products of the arachidonic acid cascade. These products, in particular thromboxane and platelet activating factor, are believed to play a deleterious role in ischemic brain. Received September 20, 1990 ; accepted April 11, 1991. let activating factor at the receptor level reduced the volume of focal cortical infarcts.
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A series of 4-thiazolidinone compounds represented by LY178002 {5-[3,5-bis(l,l-dimethylethyl)-4-hydroxyphenyl]methylene-4-thiazolidinone} have been described as modulators of the arachidonic acid cascade.
11 LY178002 has been shown to inhibit the activities of phospholipase A 2, fatty acid cyclooxygenase, and 5-lipoxygenase. 12 Another property of LY178002 can be inferred from its chemical structure ( Figure 1 ). The aromatic portion of the molecule contains the structure of butylated hydroxytolune, a known antioxidant. Thus, from a mechanistic standpoint, we decided that the ability of LY178002 to inhibit lipid peroxidation needed to be evaluated because of the di-terf-butylphenol backbone of the compound, a feature common to many antioxidants. Because of the ability of LY178002 to inhibit key enzymes of the arachidonic acid cascade and its strong potential to act as an antioxidant, we thought it would be of interest to study this compound as an anti-ischemic agent in an animal model of global forebrain ischemia.
Materials and Methods
We used male Wistar rats from Hilltop Lab Animals, Inc., Scottdale, Pa., weighing 250-280 g. The rats were subjected to 30 minutes of forebrain ischemia by the method of Pulsinelli and Brierley. 13 Following the period of ischemia, the rats were allowed free access to food and water. Seventy-two hours following the ischemia, the animals were killed by an overdose of anesthetic and the brains were removed, frozen, and sectioned through the striatum and hippocampus. Sections were mounted on glass slides and stained with hematoxylin and eosin. Damage to the right and left hemispheres of the brain was scored on a scale of 0 to 3, where 0 indicated no cell loss; 1, that approximately Vi of the cells had died; 2, that approximately % of the cells had died; and 3, that there was a >90% loss of cells. The brains were scored in a blinded fashion. Average damage scores for each group were computed, and the level of significance was calculated using the Mann-Whitney U test.
LY178002 was suspended in 2% aqueous acacia and administered orally. In experiment 1, LY178002 was given at a dose of 150 mg/kg 2 hours prior to occlusion, 4 hours after occlusion, and again 24 hours later {n=\\). In experiment 2, LY178002 was given at a dose of 50 mg/kg 2 hours prior to occlusion, 4 hours after occlusion, and again 24 hours later (n=13). In experiment 3, LY178002 was given at a dose of 50 mg/kg 15 minutes before and 4 hours after occlusion and again 24 hours later (n=ll). In each experiment, the LY178002-treated rats were compared with acacia vehicle-treated rats (n=9, 19, and 9 for experiments 1, 2, and 3, respectively). During the period of ischemia and for 30 minutes after ischemia, the rat's body temperature was regulated at 37°C. Body temperature was measured by means of a rectal probe and regulated at 37°C by a Yellow Springs Instrument feedback system (Yellow Springs, Ohio) that turned on a heat lamp suspended above the rat when the temperature dropped below 37°C.
Peroxidation of the vesicular membrane lipids was conducted by incubation of a supernatant fraction prepared from a low-speed centrifugation (19,800g for 15 minutes) of brain homogenate. Frozen mature stripped rabbit brain (Pel-Freez Biologicals, Rogers, Ark.) was thawed, minced, and homogenized in 25 mM Tris hydrochloride containing 0.5 M potassium chloride, pH 7.5 (10% wt:vol). The supernatant fraction (0.5 ml) was incubated in the presence of 220 /iM adenosine diphosphate (ADP) and 2 fiM ferric chloride at 37°C for 1 hour. LY178002 was added immediately before the ADP and ferric chloride. The reaction was terminated by the addition of 0. 4 acid-reactive substance reagent (0.02% trichloroacetic acid and 0.8% thiobarbituric acid). After boiling for 15 minutes, the samples were acidified by the addition of 0.5 ml of 2.3N hydrochloric acid. The mixtures were then extracted with 1 ml n-butanol, and after centrifugation at 3,000g for 5 minutes, the absorbancy of the butanol phase was determined at 535 nm in a Spectronics-20 spectrophotometer (Westbury, N.Y.). A standard curve of malondialdehyde (Aldrich Chemical Co., Milwaukee, Wise.) was also constructed, and the amount of malondialdehyde in the reaction mixture was determined from linear regression analysis of the standard curve. Inhibitors were added to the reaction mixture in 5 pi\ dimethyl sulfoxide.
Results Seventy-two hours after 30 minutes of global forebrain ischemia in rats, the hippocampus and striatum show massive neuronal damage. The hippocampal CA, pyramidal cells are generally totally obliterated; the majority of neurons in the corpus striatum die, except on occassion the most medial part of the striatum that borders on the third ventricle survives. In experiment 1 (Table 1) , the administration of 150 mg/kg LY178002 significantly protected both the hippocampus (p=0.0006) and striatum (/?=0.007). In the hippocampus, neurons in the more lateral aspects of the CA ^ layer were most often protected. In experiment 2 (Table 2) , the administration of a lower dose (50 mg/kg) of LY178002 2 hours prior to four-vessel occlusion showed significant protection of the hippocampus (p=0.025) and significantly reduced damage in the striatum (p=0.005). The degree of hippocampal protection was not as great as that seen after the 150 mg/kg dose. In experiment 3 (Table 3 ), the administration of 50 mg/kg LY178002 15 minutes rather than 2 hours before ischemia significantly (/?=0.04) reduced hippocampal damage. The degree of protection was as great as that seen when the compound was given 2 hours prior to ischemia. No sections from the striatum were made in experiment 3. In brain homogenates, the addition of iron or iron-containing substances such as ferritin or methemoglobin causes a large increase in the rate of formation of thiobarbituric acid-reactive substances. The methemoglobin-mediated oxidant damage to the central nervous system is known to require endogenous ascorbate, which is present in high concentrations in the brain. 14 In the present lipid peroxidation assay, supernatant from a low-speed centrifugation of rabbit brain homogenate was used as the source of lipid membrane and ascorbate. Under our assay conditions, thiobarbituric acid-reactive substance formation was linear for 1 hour (Figure 2 ). LY178002 was shown to be an effective inhibitor of lipid peroxidation, with near-complete inhibition at 500 nM. However, the concentration-response curve for such inhibition was very steep (Figure 3 ).
Discussion
The four-vessel occlusion model in rats produces incomplete global cerebral ischemia with reperfusion. The 30-minute period of ischemia used in this study results in profound and highly reproducible neuronal damage in both the CAj layer of the hippocampus and the corpus striatum. Few substances have been found to be of therapeutic benefit in global ischemia of 30 minutes' duration. The administration of LY178002 in this model significantly attenuated ischemia-induced damage.
The mechanism of the protective effect of LY178002 is unclear; however, several alternatives exist. Our results demonstrate that LY178002 inhibits iron-dependent lipid peroxidation. During ischemia and subsequent reperfusion, oxidative free radical reactions are probably occurring. Our laboratory and others 15 " 17 have reported the massive release of catecholamines during ischemia and that when the nigrostriatal dopaminergic tract is destroyed by 6-hydroxydopamine, ischemic damage in the striatum is ameliorated. 2 ' 18 This massive release of dopamine can contribute to ischemic cell death by giving rise to 20 supports the present view. LY178002 may exert its protective effect in the striatum by scavenging free radicals that result from dopamine oxidation or by terminating free radical chain reactions in the lipid bilayer.
Globus et al, 21 however, recently presented evidence that the damage from catecholamines during ischemia may have a component that is receptormediated. These authors reported that the administration of a dopamine Dl receptor blocker along with an excitatory amino acid antagonist reduced ischemia-induced damage in the hippocampus in a model of global ischemia.
Many investigators have proposed glutamate neurotoxicity as a source of neuronal damage in response to ischemia. It is possible, however, that even glutamate-induced damage may ultimately have a free radical-mediated component. Murphy et al 22 reported that antioxidants could block glutamate excitotoxicity in a neuroblastoma cell line. Similarly, other investigators found that kainate neurotoxicity in vitro could be blocked by free radical scavengers. 23 Thus, regardless of the source that triggers the chain of events that leads to cell death after ischemia, there may ultimately be a free radical component that can be blocked by lipid peroxidation inhibitors such as LY178002.
Detection of free radicals during acute cerebral ischemia in vivo has been difficult. However, recent reports showing a reduction in neuronal damage in ischemia models after treatment with agents believed to block free radical mechanisms support the idea of free radical involvement in ischemia-induced damage. These agents include dimethylthiourea, 24 superoxide dismutase, 25 U74006F, 26 and certain di-tertbutylphenols. 27 The inhibition of key enzymes of the arachidonic acid cascade suggests other mechanisms that may account for some of the protective effects of LY178002. Inhibition of phospholipase A 2 is one of the more attractive of these mechanisms. For example, the production of thromboxanes and platelet activating factor has been proposed to have a role in ischemia-induced damage. - 10 The increase in concentrations of free fatty acids reported to occur during ischemia 5 probably results from activation of calcium-dependent phospholipase A2. 28 In addition to enhancing the formation of thromboxanes and platelet activating factor, phospholipase A 2 attacks the integrity of cell membranes. This action of phospholipase A 2 can be an additional source of cellular damage during ischemia. Increased production of leukotrienes has also been reported to occur in ischemic brain. 29 However, the evidence implicating leukotrienes as having a role in ischemic damage is certainly not compelling at this time. In our ischemia model the administration of leukotriene D4/E4 antagonists has shown no benefit (J.A. Clemens, M.E. Roush, and K. Rash, unpublished observations).
In conclusion, there are reasons to believe that several factors may participate in the cascade of events that ultimately lead to cell death after ischemia. At the present time, the major mechanism of the protective effect of LY178002 against ischemic damage is unclear. LY178002 is an example of a single agent capable of attacking multiple mechanisms that may be part of the cascade of degenerative events leading to ischemic cell death. Agents similar to LY178002 may eventually prove to be of clinical value in limiting damage from cerebral ischemia.
